2 Under-the-Radar Biotech Growth Engines: Platform Scalability vs. Commercial Execution in 2026

The structural setup for scalable biotech growth in 2026 is clearer than it has been in years. The sector's momentum is no longer just hope-it's a rally backed by concrete capital flows and a powerful industry-wide need for renewal. The Nasdaq Biotechnology Index's 33.8% rally in 2025 was the headline event, but the real story is the disciplined capital that followed. That surge, driven by M&A and clinical wins, has set a positive tone for the year ahead.

The most powerful tailwind is a looming structural shift in the pharmaceutical industry. A recent Stifel biotech outlook report estimates that over 40% of big pharma revenue is at risk from patent expirations in the next six years. This isn't a distant threat; it's a direct catalyst for acquisition demand. As major companies look to replenish their pipelines and replace lost revenue, they are becoming active buyers. This dynamic helped drive a notable pickup in M&A activity in the second half of 2025, a trend forecasters expect to carry into 2026. The capital markets are responding, but with selectivity. While U.S. biotech IPOs hit a decade-low in 2025, they are set to pick up, with investors now favoring companies with mature pipelines and positive data. In practice, this means dealmaking is becoming more targeted, focused on assets with a clear path to clinical and commercial success.

This capital discipline is directly fueling the next wave of scalable platforms. Record investment is flowing into technologies that promise repeatability and industrialization. AI-driven drug discovery, CRISPR gene editing, and mRNA are attracting unprecedented funding, with the three sectors collectively commanding more than $666 billion in disclosed funding. These are not just experimental ideas; they are becoming the engines for a new generation of pharmaceutical breakthroughs. The bottom line is that 2026 presents a unique opportunity. The market is optimistic, the industry needs renewal, and the capital is being directed toward the scalable platforms that can deliver it. For growth investors, the environment favors companies that can demonstrate not just a single promising drug, but a business model built for expansion.

Halozyme Therapeutics: A Platform Play for Scalable Market Penetration

Halozyme Therapeutics presents a classic platform growth story, where a foundational technology is being leveraged to drive scalable revenue and market penetration. The company's core asset is its proprietary ENHANZE drug-delivery technology, a recombinant human hyaluronidase enzyme that temporarily breaks down tissue barriers to enhance the absorption and dispersion of injected drugs. This isn't a single-product gamble; it's a repeatable platform designed to de-risk and accelerate commercialization for partners.

The immediate catalyst is a landmark global collaboration announced in December 2025 with Takeda. Under the exclusive license agreement, Takeda gains rights to use Halozyme's technology to enable the subcutaneous (SC) delivery of its marketed biologic, vedolizumab (sold as ENTYVIO). This is a strategic win for Halozyme, as it provides a clear, milestone-driven revenue stream. The deal grants Takeda access to a technology that is already commercially validated, allowing it to offer patients a more convenient, less time-intensive treatment option. For Halozyme, this partnership is a direct monetization of its platform, converting a scientific asset into a predictable income stream while expanding the utility of its core technology.

The scale of the opportunity is immense. Vedolizumab is approved for ulcerative colitis and Crohn's disease, with total global exposure surpassing one million patient years to date. This massive existing patient base represents a vast TAM for the SC formulation. By enabling a subcutaneous route, Takeda aims to capture a broader segment of patients who may prefer or require less frequent, clinic-based infusions. The platform model here offers a significant advantage: Halozyme avoids the high costs and execution risks of building its own global sales force and navigating complex healthcare systems. Instead, it partners with a seasoned commercial giant like Takeda, which has the infrastructure to drive adoption. This partnership structure inherently lowers Halozyme's commercial risk while allowing it to capture value at each stage of the development and launch process.

More broadly, this deal underscores the platform's scalability. The ENHANZE technology is not limited to vedolizumab. It is designed to be a generic tool that can be applied to other biologics, potentially creating a portfolio of licensing deals. This model offers higher margin potential than single-product commercialization because the incremental cost of applying the technology to a new drug is relatively low once the platform is established. For growth investors, Halozyme's setup in 2026 is compelling. It has a proven technology, a major partner, and a clear path to monetize a huge existing market. The company is shifting from a pure-play developer to a scalable platform provider, a transition that aligns perfectly with the capital markets' current preference for de-risked, repeatable business models.

Catalyst Pharmaceuticals: Commercial-Stage Growth and Forbes Validation

Catalyst Pharmaceuticals exemplifies a different kind of growth story-one built on commercial execution and defensible niche dominance. While Halozyme scales through a platform, Catalyst grows by mastering the commercialization of rare-disease therapies. Its recent inclusion on Forbes' list of America's Most Successful Small-Cap Companies for 2026, ranking 11 out of 100, is a formal validation of that model. The ranking, based on a five-year track record weighted toward recent performance, highlights a company that has consistently delivered on sales growth, profitability, and shareholder returns.

The foundation of Catalyst's success is its focus on rare and difficult-to-treat diseases. This niche provides a powerful economic moat. By targeting conditions with limited treatment options, the company can command premium pricing and build strong patient loyalty. This strategy translates directly to exceptional profitability, as evidenced by its gross margin of 79.21%. More importantly, it creates a predictable revenue stream. The company's three commercial therapies-Fycompa, Firdapse, and Agamree-serve as a diversified engine, allowing it to offset declines in one product with growth in others. For instance, while Fycompa sales have faced pressure, strong gains from Agamree have helped drive overall revenue growth.

This commercial strength is now being recognized by the market. Catalyst's stock has climbed over 25% in the past year, a performance that reflects investor confidence in its scalable commercial model. The Forbes honor is not just a pat on the back; it's a signal that the company's approach of in-licensing, developing, and commercializing niche therapies is a proven path to success. With a cash-rich balance sheet and a clear pipeline, Catalyst is positioned to continue expanding its footprint in these high-value markets. For growth investors, the story here is about execution: turning a focused therapeutic portfolio into sustained, high-margin revenue growth.

Comparative Growth Thesis and the Broader Under-the-Radar Landscape

The two investment theses we've examined represent distinct paths to scalable growth in 2026. Halozyme Therapeutics is a pure platform play, where the core technology is the product. This model offers higher inherent scalability and lower commercial risk because the company avoids the heavy costs of building its own sales force and navigating complex healthcare systems. Its recent deal with Takeda to enable subcutaneous delivery of vedolizumab is a textbook example: a milestone-driven revenue stream from a technology applied to a massive existing market. The key vulnerability here is partner execution; Halozyme's growth is directly tied to Takeda's ability to successfully launch and market the new formulation.

Catalyst Pharmaceuticals, by contrast, is a commercial-stage execution story. It has proven its ability to in-license, develop, and commercialize niche therapies, as validated by its ranking 11 out of 100 on Forbes' list of America's Most Successful Small-Cap Companies for 2026. This model provides more predictable, near-term revenue growth and exceptional profitability, with a gross margin of 79.21%. However, it faces the classic challenge of market saturation within its focused therapeutic areas. Growth here depends on expanding into new indications and offsetting patent cliffs with new launches, a path that requires continuous commercial success.

For growth investors, the key metric for both models is the rate of market penetration and the expansion of their Total Addressable Market (TAM). Halozyme's TAM is defined by the number of biologics that can be adapted with its ENHANZE technology. Catalyst's TAM is defined by the number of rare diseases it can address and the patient populations it can capture within those niches.

Beyond these two clear cases, the under-the-radar landscape for 2026 includes other potential growth engines. One is AI-driven diagnostics, exemplified by AIML Innovations. Its platform for high-volume cardiac workflows targets a massive and growing clinical need, with efficiency gains translating directly into operating leverage as adoption scales. Another is clinical-stage oncology, represented by Oncolytics Biotech. Its immunotherapy platform is designed to work alongside existing cancer treatments, broadening its relevance across a wide range of indications and creating a potential pipeline of combination-therapy partnerships.

The bottom line is that 2026 favors companies that can demonstrate a clear path to scaling their TAM. Whether through a repeatable platform or a mastered commercial model, the winners will be those that can execute on partnerships and data readouts to drive penetration. The environment is disciplined, but the capital is flowing toward de-risked assets with a proven ability to grow.

Catalysts, Risks, and What to Watch in 2026

The growth trajectories for Halozyme and Catalyst are set to be defined by specific milestones in the coming year. For Halozyme, the immediate focus is on the commercialization of its licensed assets and the expansion of its platform's addressable market. The landmark deal with Takeda is a major step, but investors must watch for the successful launch of the subcutaneous vedolizumab formulation. More importantly, the company's scalability hinges on securing new partnership announcements that apply its ENHANZE technology to additional biologics. Each new license would validate the platform's versatility and open a fresh revenue stream, directly expanding its Total Addressable Market.

For Catalyst Pharmaceuticals, the growth engine runs on commercial execution. The company's path in 2026 will be measured by its ability to drive sales growth across its portfolio, secure new indication approvals for its existing therapies, and expand into new geographic markets. Its recent Forbes recognition underscores a model built on consistent commercial success, and maintaining that momentum requires a steady pipeline of positive data and regulatory wins. Any delays or setbacks in these areas could slow the predictable revenue growth that has defined the company.

The primary over-arching risk for both companies-and the entire sector-is continued regulatory volatility, particularly at the FDA. While approvals have been comparable to recent years, the agency's evolving dynamics and leadership turnover create uncertainty. This risk could delay critical milestones, from clinical trial submissions to new drug applications, directly impacting the growth trajectories of companies like Halozyme and Catalyst. As one analyst noted, despite a rally in the second half of 2025, policy risk remains a headwind. In a year defined by strategic partnerships and innovation-led growth, any regulatory friction could disrupt the carefully laid plans for market penetration.